Responsibilities
Health economic evaluation; Health economic modelling
Background
AHUS/HØKH: 2021->
FHI/SMHB: 2016 ->
UiT/ISM: 2019-2021
UiO/HELED: 2013-2020?
OUS/OCBE: 2013-2016
NOKC/OLH: 2004-2014
FHI/EPFO: 2000-2009
SINTEF/SMM: 2002-2003
FFI: 2001-2002
Projects and publications
- Exposure to heat and air pollution in EUrope – cardiopulmonary impacts and benefits of mitigation and adaptation (EXHAUSTION)
- HEV vaksinestudie hos fertile kvinner i Bangladesh og risikofaktorer for alvorlig HEV
- Infeksjonssykdommers epidemiologi i Østfold
- NCDNOR
- Norsk ungdoms sårbarhet for smittsom hjernehinnebetennelse (NUSS)
- Olena (Lena) Mandrik, J.L. (Hans) Severens, Ariel Bardach, Salah Ghabri, Candyce Hamel, Tim Mathes, Luke D. Vale, Torbjørn Wisløff, Jeremy D. Goldhaber-Fiebert, (2021). Critical Appraisal of Systematic Reviews With Costs and Cost-Effectiveness Outcomes: An ISPOR Good Practices Task Force Report. Value in Health s. 463-472. doi: 10.1016/j.jval.2021.01.002
- Gunhild Hagen, Torbjørn Wisløff, (2021). Registry data for use in health technology assessments in norway – opportunities and challenges. Norsk Epidemiologi s. 19-27. doi: 10.5324/nje.v29i1-2.4042
- Sara Sofie Viksmoen Watle, Lisbeth Meyer Næss, Gro Tunheim, Dominique A Caugant, Torbjørn Wisløff, (2021). Cost-effectiveness of meningococcal vaccination of Norwegian teenagers with a quadrivalent ACWY conjugate vaccine. Human Vaccines & Immunotherapeutics doi: 10.1080/21645515.2021.1880209
- Synne-Kristin Hoffart Bøhn, Hanne Cathrine Lie, Kristin Valborg Reinertsen, Sophie Dorothea Fosså, Hege Sagstuen Haugnes, Cecilie E. Kiserud, Jon Håvard Loge, Torbjørn Wisløff, Lene Thorsen, (2020). Lifestyle among long-term survivors of cancers in young adulthood. Supportive Care in Cancer s. 289-300. doi: 10.1007/s00520-020-05445-6
- Andrew H. Briggs, Daniel A. Goldstein, Erin Kirwin, Rachel Meacock, Ankur Pandya, David J. Vanness, Torbjørn Wisløff, (2020). Estimating (quality-adjusted) life-year losses associated with deaths: With application to COVID-19. Health Economics doi: 10.1002/hec.4208
- Lene Thorsen, Hege Sagstuen Haugnes, Sophie Dorothea Fosså, Marianne Brydøy, Torgrim Tandstad, Torbjørn Wisløff, Gunhild Maria Gjerset, Elisabeth Edvardsen, Karl-Otto Larsen, Per Morten Sandset, Carola Henriksson, Truls Raastad, Helene Francisca Stigter Negaard, (2020). Thromboembolic events after high-intensity training duringcisplatin-based chemotherapy for testicular cancer: Casereports and review of the literature. International Journal of Cancer s. 3189-3198. doi: 10.1002/ijc.33151
- Hasse Melbye, Jon Helgeland, Øystein Karlstad, Inger Ariansen, Arnulf Langhammer, Torbjørn Wisløff, Per Nafstad, Wenche Nystad, (2020). Is the disease burden from COPD in Norway falling off? A study of time trends in three different data sources. The International Journal of Chronic Obstructive Pulmonary Disease s. 323-334. doi: 10.2147/COPD.S235106
- Elma Jelin, Torbjørn Wisløff, Øystein Kalsnes Jørstad, Turid Heiberg, Morten Carsten Moe, (2019). Patient-reported outcome measures in the management of neovascular age-related macular degeneration: a 1-year prospective study. BMJ Open Ophthalmology s. 1-8. doi: 10.1136/bmjophth-2019-000353
- Håvard Haugnes, Petter Elstrøm, Oliver Kacelnik, Urszula Agnieszka Jadczak, Torbjørn Wisløff, Birgitte Freiesleben de Blasio, (2019). Financial and Temporal Costs of Patient Isolation in Norwegian Hospitals. Journal of Hospital Infection doi: 10.1016/j.jhin.2019.11.012
- Elma Jelin, Torbjørn Wisløff, Morten Carsten Moe, Turid Heiberg, (2019). Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ 25) in a Norwegian population of patients with neovascular age-related macular degeneration compared to a control population. Health and Quality of Life Outcomes s. 1-9. doi: 10.1186/s12955-019-1203-0
- Mehdi Sahba, Anne Helene Krog, Erik Mulder Pettersen, Torbjørn Wisløff, Kjetil Gunmudson Rogne, Jon Otto Sundhagen, Syed Sajid Hussain Kazmi, (2019). Cost comparison analysis of laparoscopic versus open aortobifemoral bypass surgery: A randomized controlled trial. Open Access Journal of Clinical Trials s. 11-18. doi: 10.2147/OAJCT.S192552
- Torbjørn Wisløff, Liv Mundal, Kjetil Retterstøl, Jannicke Igland, Ivar Sønbø Kristiansen, (2019). Economic evaluation of lipid lowering with PCSK9 inhibitors in patients with familial hypercholesterolemia: Methodological aspects. Atherosclerosis s. 140-146. doi: 10.1016/j.atherosclerosis.2019.06.900
- Håvard Haugnes, Elmira Flem, Torbjørn Wisløff, (2019). Healthcare costs associated with varicella and herpes zoster in Norway. Vaccine s. 3779-3784. doi: 10.1016/j.vaccine.2019.05.063
- Gunhild Maria Gjerset, Cecilie E. Kiserud, Jon Håvard Loge, Sophie Dorothea Fosså, Torbjørn Wisløff, Sævar Berg Gudbergsson, Line Merethe Oldervoll, Lene Thorsen, (2019). Changes in fatigue, health-related quality of life and physical activity after a one-week educational program for cancer survivors. Acta Oncologica s. 682-689. doi: 10.1080/0284186X.2018.1562210
- Stig Evensen, Torbjørn Wisløff, June Ullevoldsæter Lystad, Helen Bull, Egil Wilhelm Martinsen, Torill Ueland, Erik Falkum, (2019). Exploring the potential cost-effectiveness of a vocational rehabilitation program for individuals with schizophrenia in a high-income welfare society. BMC Psychiatry s. 1-10. doi: 10.1186/s12888-019-2130-7
- Synne-Kristin Hoffart Bøhn, Lene Thorsen, Cecilie E. Kiserud, Sophie Dorothea Fosså, Hanne Cathrine Lie, Jon Håvard Loge, Torbjørn Wisløff, Hege Sagstuen Haugnes, Kristin Valborg Reinertsen, (2019). Chronic fatigue and associated factors among long-term survivors of cancers in young adulthood. Acta Oncologica s. 753-762. doi: 10.1080/0284186X.2018.1557344
- Camilla Andreasen, Lene Bergendal Solberg, Trude Basso, Tove Tveitan Borgen, Cecilie Dahl, Torbjørn Wisløff, Gunhild Hagen, Ellen M Apalset, Jan-Erik Gjertsen, Wender Figved, Lars Michael Hübschle, Jens-Meinhard Stutzer, Jan Elvenes, Ragnar Martin Joakimsen, Unni Syversen, Erik Fink Eriksen, Lars Nordsletten, Frede Jon Frihagen, Tone Kristin Omsland, Åshild Bjørnerem, (2018). Effect of a Fracture Liaison Service on the Rate of Subsequent Fracture Among Patients With a Fragility Fracture in the Norwegian Capture the Fracture Initiative (NoFRACT): A Trial Protocol. JAMA Network Open doi: 10.1001/jamanetworkopen.2018.5701
- Synne-Kristin Hoffart Bøhn, Sophie Dorothea Fosså, Torbjørn Wisløff, Lene Thorsen, (2018). Physical activity and associations with treatment-induced adverse effects among prostate cancer patients. Supportive Care in Cancer s. 1001-1011. doi: 10.1007/s00520-018-4389-5
- Elma Jelin, Torbjørn Wisløff, Morten Carsten Moe, Turid Heiberg, (2018). Development and testing of a patient-derived questionnaire for treatment of neovascular age-related macular degeneration: dimensions of importance in treatment of neovascular age-related macular degeneration. Acta Ophthalmologica s. 804-811. doi: 10.1111/aos.13847
- Mette Lise Lousdal, Mette H. Møller, Ivar Sønbø Kristiansen, Mette Kalager, Torbjørn Wisløff, Henrik Støvring, (2018). The Screening Illustrator: separating the effects of lead-time and overdiagnosis in mammography screening. European Journal of Public Health s. 1138-1142. doi: 10.1093/eurpub/cky085
- Torbjørn Wisløff, Richard Aubrey White, Olav Dalgard, Ellen Johanna Amundsen, Hinta Meijerink, Hilde Kløvstad, (2018). Feasibility of reaching world health organization targets for hepatitis C and the cost‐effectiveness of alternative strategies. Journal of Viral Hepatitis s. 1066-1077. doi: 10.1111/jvh.12904
- Max Korman, Kjetil Retterstøl, Ivar Sønbø Kristiansen, Torbjørn Wisløff, (2018). Are PCSK9 Inhibitors Cost Effective?. PharmacoEconomics (Auckland) s. 1031-1041. doi: 10.1007/s40273-018-0671-0
- Øyvind Bleka, Torbjørn Wisløff, Pål Skage Dahlberg, Veslemøy Rolseth, Thore Egeland, (2018). Advancing estimation of chronological age by utilizing available evidence based on two radiographical methods. International journal of legal medicine (Print) s. 217-229. doi: 10.1007/s00414-018-1848-y
- Liv Mundal, Jannicke Igland, Marit Bragelien Veierød, Kirsten Bjørklund Holven, Leiv Ose, Randi Selmer, Torbjørn Wisløff, Ivar Sønbø Kristiansen, Grethe S. Tell, Trond Paul Leren, Kjetil Retterstøl, (2018). Impact of age on excess risk of coronary heart disease in patients with familial hypercholesterolaemia. Heart s. 1600-1607. doi: 10.1136/heartjnl-2017-312706
- Torbjørn Wisløff, Richard Aubrey White, Olav Dalgard, Ellen Johanna Amundsen, Hinta Meijerink, Astrid Louise Løvlie, Hilde Kløvstad, (2018). Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway. PharmacoEconomics (Auckland) s. 591-601. doi: 10.1007/s40273-017-0604-3
- Max Korman, Torbjørn Wisløff, (2018). Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting. European Heart Journal s. 15-22. doi: 10.1093/ehjcvp/pvx010
- Irene Lie, Stein Ove Danielsen, Theis Tønnessen, Svein Solheim, Marit Leegaard, Leiv Sandvik, Torbjørn Wisløff, Jonny Vangen, Tor Henning Røsstad, Philip Moons, (2017). Determining the impact of 24/7 phone support on hospital readmissions after aortic valve replacement surgery (the AVRre study): Study protocol for a randomised controlled trial. Trials s. 1-9. doi: 10.1186/s13063-017-1971-y
- Anne Helene Krog, Mehdi Sahba, Erik Mulder Pettersen, Torbjørn Wisløff, Jon Otto Sundhagen, Syed Sajid Hussain Kazmi, (2017). Cost-utility analysis comparing laparoscopic vs open aortobifemoral bypass surgery. Vascular Health and Risk Management s. 217-224. doi: 10.2147/VHRM.S138516
- Gunhild Maria Gjerset, Jon Håvard Loge, Cecilie E. Kiserud, Sophie Dorothea Fosså, Sævar Berg Gudbergsson, Line Merethe Oldervoll, Torbjørn Wisløff, Lene Thorsen, (2017). Perceived needs for different components in a rehabilitation program among cancer survivors with chronic fatigue compared to survivors without chronic fatigue. Acta Oncologica s. 245-253. doi: 10.1080/0284186X.2016.1266091
- Eva Pike, Vida Hamidi, Tove Ringerike, Torbjørn Wisløff, Marianne Klemp, (2017). More Use of Peritoneal Dialysis Gives Significant Savings: A Systematic Review and Health Economic Decision Model. Journal of Clinical Medicine Research s. 104-116. doi: 10.14740/jocmr2817w
- Erik Lønnmark Werner, Kjersti Storheim, Ida Løchting, Torbjørn Wisløff, Margreth Grotle, (2016). Cognitive patient education for low back pain in primary care: A cluster randomized controlled trial and cost-effectiveness analysis. Spine s. 455-462. doi: 10.1097/BRS.0000000000001268
- Gunhild Hagen, Torbjørn Wisløff, Ivar Sønbø Kristiansen, (2016). The predicted lifetime costs and health consequences of calcium and vitamin D supplementation for fracture prevention—the impact of cardiovascular effects. Osteoporosis International s. 2089-2098. doi: 10.1007/s00198-016-3495-9
- Torbjørn Wisløff, Dan Atar, (2016). Cost-effectiveness of antiplatelet drugs after percutaneous coronary intervention. European Heart Journal - Quality of Care and Clinical Outcomes s. 52-57. doi: 10.1093/ehjqcco/qcv023
- Stig Evensen, Torbjørn Wisløff, June Ullevoldsæter Lystad, Helen Christine Bull, Toril Ueland, Erik Falkum, (2016). Prevalence, employment rate, and cost of schizophrenia in a high-income welfare society: A population-based study using comprehensive health and welfare registers. Schizophrenia Bulletin s. 476-483. doi: 10.1093/schbul/sbv141
- Käthe Birgitte Meyer, Astrid Klopstad Wahl, Ida Torunn Bjørk, Torbjørn Wisløff, Anders Hartmann, Marit Helen Andersen, (2016). Long-term, self-reported health outcomes in kidney donors. BMC Nephrology doi: 10.1186/s12882-016-0221-y
- Torbjørn Wisløff, Gunhild Hagen, Marianne Klemp, (2014). Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation. PharmacoEconomics (Auckland) s. 601-612. doi: 10.1007/s40273-014-0152-z
- Torbjørn Wisløff, Gunhild Hagen, Vida Hamidi, Espen Movik, Marianne Klemp, Jan Abel Olsen, (2014). Estimating QALY gains in applied studies: A review of cost-utility analyses published in 2010. PharmacoEconomics (Auckland) s. 367-375. doi: 10.1007/s40273-014-0136-z
- Henrik Støvring, CG Harmsen, Torbjørn Wisløff, DE Jarbøl, Jørgen Nexøe, Jesper Bo Nielsen, Ivar Sønbø Kristiansen, (2013). A competing risk approach for the European Heart SCORE model based on cause-specific and all-cause mortality. European Journal of Preventive Cardiology (EJPC) s. 827-836. doi: 10.1177/2047487312445425
- Torbjørn Wisløff, Dan Atar, Ivar Sønbø Kristiansen, (2013). Cost Effectiveness of Drug-Eluting Stents as Compared With Bare Metal Stents in Patients With Coronary Artery Disease. American Journal of Therapeutics s. 596-601. doi: 10.1097/MJT.0b013e3182211a01
- Gunhild Hagen, Torbjørn Wisløff, Marianne Klemp, (2013). Helseøkonomisk evaluering ved Nasjonalt kunnskapssenter for helsetjenesten. Norsk Epidemiologi s. 157-164. doi: 10.5324/nje.v23i2.1638
- Kirsten Muri Boberg, Torbjørn Wisløff, Karl Sæbjørn Kjøllesdal, Henrik Støvring, Ivar Sønbø Kristiansen, (2013). Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid. Alimentary Pharmacology and Therapeutics s. 794-803. doi: 10.1111/apt.12435
- Torbjørn Wisløff, Randi Selmer, Sigrun Halvorsen, Atle Fretheim, Ole Frithjof Norheim, Ivar Sønbø Kristiansen, (2012). Choice of generic antihypertensive drugs for the primary prevention of cardiovascular disease - A cost-effectiveness analysis. BMC Cardiovascular Disorders doi: 10.1186/1471-2261-12-26
- Tale Norbye Wien, Eva Pike, Torbjørn Wisløff, Anne Cathrine Staff, Sigbjørn Smeland, Marianne Klemp, (2012). Cancer risk with folic acid supplements: a systematic review and meta-analysis. BMJ Open doi: 10.1136/bmjopen-2011-000653
- Peder Andreas Halvorsen, Torbjørn Wisløff, Henrik Støvring, Olaf Gjerløw Aasland, Ivar Sønbø Kristiansen, (2011). Therapeutic decisions by number needed to treat and survival gains: a cross-sectional survey of lipid-lowering drug recommendations. British Journal of General Practice s. e477-e483. doi: 10.3399/bjgp11x588448
- Torbjørn Wisløff, Odd O. Aalen, Ivar Sønbø Kristiansen, (2011). Considerable variation in NNT - A study based on Monte Carlo simulations. Journal of Clinical Epidemiology s. 444-450. doi: 10.1016/j.jclinepi.2010.04.025
- Torbjørn Wisløff, Odd O. Aalen, Ivar Sønbø Kristiansen, (2010). Considerable variation in NNT - A study based on Monte Carlo simulations. Journal of Clinical Epidemiology doi: 10.1016/j.jclinepi.2010.04.025
- S Berntsen, Torbjørn Fosen Wisløff, Per Nafstad, Wenche Nystad, (2008). Lung function increases with increasing level of physical activity in school children. Pediatric Exercise Science s. 402-410.
- Are Stuwitz Berg, Ellen Furuseth, Margrethe Greve-Isdahl, Ivar Wilhelm Grosvold, Lisbeth Meyer Næss, Hanne Magdalene Nøkleby, Jeanette Stålkrantz, Gro Tunheim, Torbjørn Wisløff, Britt Wolden, Ingeborg Sundsvalen Aaberge, Audun Aase, (2019). Kikhostevaksine til gravide – aktuelt for Norge?
- Enrique Jimenez, Torbjørn Wisløff, Marianne Klemp, (2014). Cost-effectiveness of a HPV-vaccination catch-up program for females aged 26 years or younger in a Norwegian setting
- Eva Pike, Vida Hamidi, Tove Ringerike, Torbjørn Wisløff, Arna S. Desser, Ingrid Harboe, Marianne Klemp, (2013). Health technology assessment of the different dialysis modalities in Norway
- Torbjørn Wisløff, Tove Ringerike, Gunhild Hagen, Åsmund Reikvam, Marianne Klemp, (2013). Efficacy and cost-effectiveness of new oral anticoagulants compared to warfarin for the prevention of stroke in patients with atrial fibrillation
- Eva Pike, Tale Norbye Wien, Torbjørn Wisløff, Ingrid Harboe, Marianne Klemp, (2011). Kreftrisiko ved folsyretilskudd
- Gunhild Hagen, Torbjørn Wisløff, Jan Falch, Cathrine Lofthus, Frede Frihagen, Knut-Arne Wensaas, Lars Granum, Janicke Nevjar, Ivar Sønbø Kristiansen, Marianne Klemp, (2011). Efficacy and cost-effectiveness of alendronate for the prevention of fractures in postmenopausal women in Norway
- Torbjørn Wisløff, Tove Ringerike, Marianne Klemp, (2011). A systematic review and economic evaluation of prasugrel compared to clopidogrel after PCI
- Vida Hamidi, Torbjørn Wisløff, Tove Ringerike, Kristin Kamilla Linnestad, Ingrid Harboe, Marianne Klemp, (2010). Behandling av pasienter med akutt hjerneslag i slagenheter (med og uten tidlig støttet utskriving)
- Torbjørn Wisløff, Vida Hamidi, Tove Ringerike, Ingrid Harboe, Marianne Klemp Gjertsen, (2010). Intravenøs trombolytisk behandling av hjerneinfarkt i akuttfasen og sekundær blodproppforebyggende behandling (platehemmende behandling og antikoagulasjonsbehandling) etter hjerneslag. Medisinsk metodevurdering (HTA-rapport)
- Gunhild Hagen, Torbjørn Wisløff, Marianne Klemp, (2010). Cost-effectiveness of varenicline, bupropion and nicotine replacement therapy for smoking cessation
- Gunhild Hagen, Torbjørn Wisløff, Jan Falch, Cathrine Lofthus, Frede Frihagen, Knut-Arne Wensaas, Lars Granum, Janicke Nevjar, Ivar Sønbø Kristiansen, Marianne Klemp, (2010). Efficacy and cost-effectiveness of alendronate for the prevention of fractures in postmenopausal women in Norway
- Eva Pike, Kari Ann Leiknes, Torbjørn Wisløff, Tove Ringerike, Marianne Klemp Gjertsen, (2009). Effekt og sikkerhet av første- og annengenerasjons antipsykotika ved schizofreni hos voksne
- Torbjørn Wisløff, Randi M. Selmer, Sigrun Halvorsen, Ivar Sønbø Kristiansen, (2008). Norwegian Cardiovascular Disease Model (NorCaD) – a simulation model for estimating health benefi ts and cost consequences of cardiovascular interventions
- Torbjørn Wisløff, Ole Frithjof Norheim, Sigrun Halvorsen, Randi Selmer, Ivar Sønbø Kristiansen, (2008). Kostnader og leveårsgevinster ved medikamentell primærforebygging av hjertekarsykdom
- Eva Pike, Kristin Kamilla Linnestad, Gunhild Hagen, Aileen Rae Neilson, Torbjørn Wisløff, Marianne Klemp Gjertsen, (2008). Sammenligning av palonosetron og ondansetron med hensyn på klinisk nytte og kostnad/effekt ved forebygging av kvalme og oppkast i forbindelse med kjemoterapi hos kreftpasienter
- Torbjørn Wisløff, (2020). Nye terskelverdier som følge av COVID-19?.
- Torbjørn Wisløff, (2020). Trygt å trene ved treningssentre?. Aftenposten (morgenutg. : trykt utg.) s. 35-35.
- Anders Skyrud Danielsen, Torbjørn Wisløff, Unni Gopinathan, (2020). Usikkert om barn og smitte. Dagbladet
- Torbjørn Wisløff, (2020). Restriksjonene – og dødeligheten. Dagens medisin
- Torbjørn Wisløff, (2019). Samfunnsøkonomiske konsekvenser ved kreft – kreftrehabilitering i lys av dette.
- Torbjørn Wisløff, (2019). Literature Selection and Validation.
- Torbjørn Wisløff, (2019). SMDM Symposium: Value for Whom? Choice and Consequences of Perspective in Economic Evaluations.
- Natalia Kunst, Scott Grosse, Yao-Hsuan Chen, David Kim, Torbjørn Wisløff, (2019). Overview of various recommendations for health economic perspective. Symposium: Value for whom? Choice and Consequences of Perspective in Economic Evaluations..
- Elma Jelin, Turid Heiberg, Morten Carsten Moe, Torbjørn Wisløff, (2018). Patient Reported Outcome measures in neovascular Age-Related Macular Degeneration.
- Elma Jelin, Morten Carsten Moe, Torbjørn Wisløff, Turid Heiberg, (2018). Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ 25) tested in observational longitudinal study of patients with neovascular Age-related Macular Degeneration (Norwegian cohort)..
- Torbjørn Wisløff, (2017). Communication of opportunity cost.
- Elma Jelin, Turid Heiberg, Morten Carsten Moe, Torbjørn Wisløff, (2017). The development and psychometric performance of a new patient derived tool to measure important Dimensions In Treatment of Age-related Macular Degeneration (DITAMD).. Acta Ophthalmologica
- Elma Jelin, Turid Heiberg, Morten Carsten Moe, Torbjørn Wisløff, (2017). The development and psychometric performance of a new patient derived tool to measure important Dimensions In Treatment of Age-related Macular Degeneration (DITAMD)..
- Irene Lie, Stein Ove Danielsen, Theis Tønnessen, Svein Solheim, Marit Leegaard, Leiv Sandvik, Torbjørn Wisløff, Jonny Vangen, Tor Henning Røsstad, Philip Moons, (2017). Determining the impact of 24/7 phone support on hospital readmissions after aortic valve replacement surgery (the AVRre study): study protocol for a randomised controlled trial. Trials doi: 10.1186/s13063-017-1971-y
- Lene Bergendal Solberg, Frede Frihagen, Trude Basso, Clara Gram Gjesdal, Erik Fink Eriksen, Lars Nordsletten, Tone Kristin Omsland, Tove Tveitan Borgen, Wender Figved, Torbjørn Wisløff, Gunnhild Hagen, Åshild Bjørnerem, (2017). Updates on the Norwegian Capture the Fracture® Initiative (NoFRACT).
- Torbjørn Wisløff, (2017). Ny norsk terskelverdi for verdien av et godt leveår?. Tidsskrift for Den norske legeforening s. 518-518. doi: 10.4045/tidsskr.17.0137
- Torbjørn Wisløff, (2016). Prioritering og HTA i Norge.
- Elma Jelin, Turid Heiberg, Morten Carsten Moe, Torbjørn Wisløff, (2016). Patient Derived tool to measure Dimensions of Treatment in Age-related Macular Degeneration..
- Gunhild Hagen, Torbjørn Wisløff, Ivar Sønbø Kristiansen, (2016). Bør Tine rekruttere melkedrikkere?. Aftenposten (morgenutg. : trykt utg.)
- Liv Mundal, Jannicke Igland, Marit Bragelien Veierød, Kirsten Bjørklund Holven, Randi Selmer, Torbjørn Wisløff, Ivar Sønbø Kristiansen, Kjetil Retterstøl, (2016). INCIDENCE OF ACUTE MYOCARDIAL INFARCTION IN PATIENTS WITH GENOTYPED FAMILIAL HYPERCHOLESTEROLEMIA IN NORWAY DURING 2001-2009. Circulation s. E711-E711.
- Elma Jelin, Turid Heiberg, Morten Carsten Moe, Torbjørn Wisløff, (2015). The Development of a new Patient Derived tool to measure Dimensions of Treatment in Age-related Macular Degeneration (DiTAMD)..
- Torbjørn Wisløff, Bjarne Robberstad, (2015). Re: Markov-modellering :. Tidsskrift for Den norske legeforening doi: 10.4045/tidsskr.15.0837
- Torbjørn Wisløff, (2015). Prioriteringskriterier i helsetjenesten :. Tidsskrift for Den norske legeforening s. 1373-1375. doi: 10.4045/tidsskr.15.0228
- Gunhild Hagen, Torbjørn Wisløff, Espen Movik, Vida Hamidi, Marianne Klemp, (2014). Reporting of QALY estimation in applied and published cost-effectiveness analyses.
- Torbjørn Wisløff, (2013). Valg av antihypertensiva som primærforebyggende tiltak. BestPractice
- Torbjørn Wisløff, Gunhild Hagen, Marianne Klemp, (2013). Comparative effectiveness research on the new anticoagulants - Do we need it?. Value in Health s. A297-A297.
- Gunhild Hagen, Torbjørn Wisløff, Marianne Klemp, (2013). Towards a paradigm shift in anticoagulation? Too soon to conclude on cost-effectiveness of new anticoagulants. Value in Health s. A289-A290.
- Torbjørn Wisløff, (2012). Indirect comparisons - from a health economic viewpoint.
- Torbjørn Wisløff, (2012). Incorporating quality of efficacy documentation in health economic evaluations.
- Torbjørn Wisløff, Jim Gudgeon, (2012). REPRESENTING PARAMETER UNCERTAINTY IN DECISION MODELS: CHARACTERIZATION OF PROBABILITY DISTRIBUTIONS.
- Torbjørn Wisløff, (2012). Which distributions to use for different types of variables and how these distributions should be parametrized in models.
- Torbjørn Wisløff, Odd O. Aalen, Ivar Sønbø Kristiansen, (2012). Regarding adequate methods for comparison of effect measures - Reply. Journal of Clinical Epidemiology s. 462-463. doi: 10.1016/j.jclinepi.2011.10.005
- Gunhild Hagen, Vida Hamidi, Espen Movik, Jan Abel Olsen, Torbjørn Wisløff, (2012). Measuring QALY gains in practice: A Review of 315 CEA/CUA published in 2010.
- Torbjørn Wisløff, Tove Ringerike, Marianne Klemp, (2011). Economic evaluation of prasugrel compared to clopidogrel after percutaneous coronary intervention.
- Torbjørn Wisløff, Gunhild Hagen, Kim Rand-Hendriksen, (2011). Half-cycle correction and Simpson’s method tested in different health economic models – does it matter which method we use?.
- Ole Frithjof Norheim, Bjørn E. Gjelsvik, Tor Ole Klemsdal, Steinar Madsen, Eivind Meland, Stein Narvesen, Anne Negård, Inger Njølstad, Serena Tonstad, Frøydis Ulvin, Torbjørn Wisløff, (2011). Norway's new principles for primary prevention of cardiovascular disease: age differentiated risk thresholds. BMJ. British Medical Journal doi: 10.1136/bmj.d3626
- Gunhild Hagen, Torbjørn Wisløff, Marianne Klemp, (2010). Cost-effectiveness of Drugs for Smoking Cessation in Norway.
- Gunhild Hagen, Torbjørn Wisløff, Ivar Sønbø Kristiansen, Marianne Klemp, (2009). Cost-effectiveness of first-line treatment for osteoporosis when the drug goes generic.